Delivery Order SPE2DB22D6029-SPE2DB25FLVEH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) with a ceiling value of $1,227.78. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on November 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, non-set-aside contract is structured as a firm fixed-price delivery order with an ultimate completion date of June 17, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units, with a ceiling value of $1,358.25. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and the order is scheduled for ultimate completion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by October 20, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (30-count units) under a firm fixed-price contract valued at $1,165.05. The award was made on September 22, 2025, with an ultimate completion date of October 14, 2025. This delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Envarsus XR 1 mg tablets (100 count) with a ceiling value of $2,716.50. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by December 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) valued at $3,608.26. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and is scheduled for completion by December 4, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) valued at $1,711.94. This firm fixed-price delivery order is scheduled for completion by November 19, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive standing as a federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Envarsus XR 0.75 mg tablets (100-count) under a firm fixed price contract with a ceiling value of $1,132.07 and an ultimate completion date of December 1, 2025. This non-set-aside award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- SPE2DB22D6029Indefinite Delivery Contract
- SPE2DB22D6029-SPE2DB25FLVEHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) valued at $1,035.60. This non-competitive delivery order, which will be completed by June 24, 2025, represents a firm fixed-price transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order is executed under AmerisourceBergen's comprehensive pharmaceutical prime vendor IDC with DLA valued at $999,999,999.00 through December 2026, which authorizes the company to supply a broad range of pharmaceuticals and medical supplies to support military healthcare systems globally. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen regularly fulfills deliveries of specialty medications, generic drugs, and medical supplies across multiple therapeutic domains for defense and veteran healthcare programs. The award carries no set-aside designation and represents the typical transactional nature of delivery orders issued against this strategic federal contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 6/2/25 |